IMA203 Displays Efficacy in Heavily Pretreated Melanoma

Source: OncLive, October 2024

IMA203, a TCR-T agent targeting PRAME, was active and offered meaningful
progression-free survival (PFS) and overall survival (OS) outcomes in patients
with heavily pretreated melanoma, according to updated data from a phase 1b
study (NCT03686124) provided by Immatics NV.

At the April 25, 2024, data cutoff, all patients with melanoma who received
IMA203 (n = 28) achieved a confirmed objective response rate (ORR) of 54%
and an unconfirmed ORR of 62% with a median duration of response (DOR) of
12.1 months. The disease control and tumor shrinkage rates were 92% and
88%, respectively. The median PFS and OS were 6.0 months and not reached,
respectively.

In patients with cutaneous melanoma (n = 13), the confirmed ORR and
unconfirmed ORR were also 54% and 62%, respectively, with a median DOR of
12.1 months. The disease control and tumor shrinkage rates were 92% and 85%, respectively. The median PFS was 6.1 months, and the median OS was
15.9 months.
READ THE ORIGINAL FULL
ARTICLE